Literature DB >> 32964282

Midface Lift Plus Lipofilling Preferential in Patients with Negative Lower Eyelid Vectors: A Randomized Controlled Trial.

Mauro Barone1,2,3, Annalisa Cogliandro4,5, Rosa Salzillo4, Silvia Ciarrocchi4, Alaa Abu Hanna4, Vito Russo4, Stefania Tenna4, Paolo Persichetti4,5.   

Abstract

INTRODUCTION: In conducting this study, it was our presumption that lipofilling is a necessary and simultaneous adjunct to lifting the middle third of the face in patients with negative lower eyelid vectors, enabling satisfactory and enduring aesthetic results.
MATERIALS AND METHODS: Eligible patients met the following criteria: (1) primary midface lift in subperiosteal plane; (2) negative inferior eyelid vectors at preoperative baseline; (3) postoperative monitoring for ~ 2 years; (4) standard pre- and postoperative photo-documentation; (5) proficiency in Italian language; and (6) signed consent for study participation. Informed consent pertaining to photography allowed for subsequent publication. Pertinent patient data were also collected as follows: age, sex, duration of follow-up, type of surgical procedure, related secondary procedures, quantity of fat injected, nature of incision, and patient satisfaction level. Complete randomness was thus conferred during computer-assisted patient assignment to one of two study arms: midface lift only (group 1) or midface lift plus facial lipofilling as a concurrent operation (group 2). All patients completed Italian versions of the FACE-Q module, which were issued by e-mail approximately 2 years postoperatively. Two plastic surgeons reviewed all postoperative photographs of treated patients and rated outcomes on a scale of 1-5. Statistical analysis was powered by standard software expressing categorical data as numbers and percentages and quantitative data as means ± standard deviations.
RESULTS: Between January 2016 and March 2018, a total of 56 patients (women 48; men 8) subjected to primary midface lifts in subperiosteal plane at our Plastic Surgery Department met all criteria for study enrollment. Mean patient age was 56.5 years (range 40-70 years), and the mean follow-up period was 2.1 years (range 2-5 years). Differences in postoperative FACE-Q scoring by the two groups were significant (p < 0.01) across all domains. Outcomes in patients of group 2 remained stable during long-term follow-up, whereas significantly more secondary procedures were pursued by patients of group 1 (p < 0.01). Compared with group 1, the two reviewers encountered significantly greater satisfaction with surgical outcomes among patients of group 2 (p < 0.01).
CONCLUSIONS: In FACE-Q scoring, those undergoing lift-and-fill procedures reported the highest satisfaction levels. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Entities:  

Keywords:  FACE-Q; Face; Facelift; Lipofilling; Patient satisfaction; Quality of life

Mesh:

Year:  2020        PMID: 32964282     DOI: 10.1007/s00266-020-01971-0

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  1 in total

1.  Rejuvenation of the midface by elevating the malar fat pad: review of technique, cases, and complications.

Authors:  Benoit C De Cordier; Jorge I de la Torre; Mazin S Al-Hakeem; Laurence Z Rosenberg; Antonio Costa-Ferreira; Paul M Gardner; R Jobe Fix; Luis O Vasconez
Journal:  Plast Reconstr Surg       Date:  2002-11       Impact factor: 4.730

  1 in total
  2 in total

1.  Vertical Space Lift: Transcutaneous Lower Blepharoplasty, Subperiosteal Midface Lift, and Lower Face Lift: A Novel Technique of Buccal Fat Suspension to Medial Infraorbital Rim.

Authors:  Hadi Nural
Journal:  Aesthet Surg J Open Forum       Date:  2021-12-15

2.  Facial Rejuvenation with Concentrated Lipograft-A 12 Month Follow-Up Study.

Authors:  Lukas Prantl; Eva Brix; Sally Kempa; Oliver Felthaus; Andreas Eigenberger; Vanessa Brébant; Alexandra Anker; Catharina Strauss
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.